Steven R. Verdooner
CEO & CO-FOUNDER
Steve is a seasoned, results-driven executive with over 30 years of experience in the ophthalmology, neurology and medical device markets, with a proven track record of launching and leading successful startup businesses. He has expertise in a diverse range of business management including sales and marketing, research and development, operations and regulatory management, brand management, business development and strategic planning. Steve has a proven ability to lead and interface with key opinion leaders, advisory boards, customers, scientists, engineers, Company Boards and the financial community.
Steve serves as the CEO of NeuroVision Imaging, a company developing retinal and fluid biomarkers for neurodegenerative disease. Steve was co-founder and CEO of Ophthalmic Imaging Systems (1984-2007). OIS was a company dedicated to research, development, marketing, selling and manufacturing diagnostic medical imaging systems and informatics software for the eye care market. Steve led the initial research, market analysis, product development, commercialization strategy, and product launch for a revolutionary new imaging system that was the first of its kind in ophthalmology. Steve was involved in establishing and building the company infrastructure that took OIS to a public offering in 1992 and eventually being sold to Merge Healthcare in 2011. Steve next joined OPKO Health, Inc. as Executive Vice President. OPKO is a publicly traded specialty healthcare company (that engages in the discovery, development, and commercialization of pharmaceutical products, medical devices, vaccines, and diagnostic technologies.
Leyla Anderson, MD, PhD, D(ABMLI)*
VP, Biomarker Development
*Diplomate, American Board of Medical Laboratory Immunology (CLIA-approved)
Dr. Anderson is a medical scientist with over 20 years of experience in the areas of infectious diseases, immunology and genomics. She completed her PhD in the disciplines of microbiology and immunology and pursued post-doctoral studies at Yale University and University of California, Davis. She is also board certified in Medial Laboratory Immunology to direct high-complexity diagnostic laboratories. Her area of expertise includes laboratory medicine, diagnostic testing, biomarker assay development, regulatory compliance, laboratory management, academic research and teaching including her tenure as a lecturer at University of Oxford, UK. Prior to joining NeuroVision, Dr. Anderson directed clinical trials operations at Quest Diagnostics Clinical Trails Lab in Valencia, including biomarker assay development, validation and implementation in Global Flow Cytometry, Molecular Biology and Anatomic Pathology departments in her capacity as an Associate Biomarker Director. She also acted as a testing site Principal Investigator for multiple companion diagnostics studies. Dr. Anderson is a recipient of two Alzheimer's Drug Discovery Foundation Diagnostic Accelerator Funding awards.
Hugo Vanderstichele, PhD
Global Head of Biomarker Development
Hugo has proven expertise in the translation of protein biomarkers from concept to clinical value, including but not limited to target identification, selection and evaluation of tools & technologies (single analyte and multiplex immunoassay platforms), protein assay development (from prototyping to qualification, validation, and registration), clinical study design and execution, and market integration of assays or test concepts
He is a founder of Biomarkable and was a co-founder of ADx Neurosciences. He gained over 21 years IVD experience at Innogenetics (now Fujirebio). His experience covers various domains, including neurodegeneration, endocrinology (steroidogenesis, in-vitro fertilization, embryology), cardiovascular, infectious and autoimmune diseases.
He is a sought-after advisor in world-wide efforts to generate standard operating procedures for sample collection, storage and qualification of biomarker protein assays. He was a scientific advisor in several consortia including the Global Biomarker Standardization Consortium (ADNI), CPAD, and the Michael J Fox Foundation.
He has been the principal investigator in several multi-center projects, has authored or co-authored over 153 publications (H-index 58) and is listed as inventor on several patent applications.